Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.
dc.contributor.author | Dearnaley, D | |
dc.contributor.author | Jovic, G | |
dc.contributor.author | Syndikus, I | |
dc.contributor.author | Khoo, V | |
dc.contributor.author | Cowan, Richard A | |
dc.contributor.author | Graham, J | |
dc.contributor.author | Aird, E | |
dc.contributor.author | Bottomley, D | |
dc.contributor.author | Huddart, R | |
dc.contributor.author | Jose, C | |
dc.contributor.author | Matthews, J | |
dc.contributor.author | Millar, J | |
dc.contributor.author | Murphy, C | |
dc.contributor.author | Russell, J M | |
dc.contributor.author | Scrase, C | |
dc.contributor.author | Parmar, M | |
dc.contributor.author | Sydes, M | |
dc.date.accessioned | 2014-03-27T10:15:52Z | |
dc.date.available | 2014-03-27T10:15:52Z | |
dc.date.issued | 2014-02-25 | |
dc.identifier.citation | Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. 2014: Lancet Oncol | en |
dc.identifier.issn | 1474-5488 | |
dc.identifier.pmid | 24581940 | |
dc.identifier.doi | 10.1016/S1470-2045(14)70040-3 | |
dc.identifier.uri | http://hdl.handle.net/10541/314875 | |
dc.description.abstract | The aim of this trial was to compare dose-escalated conformal radiotherapy with control-dose conformal radiotherapy in patients with localised prostate cancer. Preliminary findings reported after 5 years of follow-up showed that escalated-dose conformal radiotherapy improved biochemical progression-free survival. Based on the sample size calculation, we planned to analyse overall survival when 190 deaths occurred; this target has now been reached, after a median 10 years of follow-up. | |
dc.language | ENG | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to The lancet oncology | en |
dc.title | Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. | en |
dc.type | Article | en |
dc.contributor.department | The Institute of Cancer Research, London, UK | en |
dc.identifier.journal | The Lancet Oncology | en |
dc.description.collection | Lymphoma Research Team | en |
html.description.abstract | The aim of this trial was to compare dose-escalated conformal radiotherapy with control-dose conformal radiotherapy in patients with localised prostate cancer. Preliminary findings reported after 5 years of follow-up showed that escalated-dose conformal radiotherapy improved biochemical progression-free survival. Based on the sample size calculation, we planned to analyse overall survival when 190 deaths occurred; this target has now been reached, after a median 10 years of follow-up. |